###begin article-title 0
###xml 57 62 <span type="species:ncbi:9606">human</span>
Lack of TAR-DNA binding protein-43 (TDP-43) pathology in human prion diseases
###end article-title 0
###begin p 1
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
###end p 1
###begin title 2
Aims
###end title 2
###begin p 3
###xml 401 406 <span type="species:ncbi:9606">human</span>
TAR-DNA binding protein-43 (TDP-43) is the major ubiquitinated protein in the aggregates in frontotemporal dementia with ubiquitin-positive, tau-negative inclusions and motor neurone disease. Abnormal TDP-43 immunoreactivity has also been described in Alzheimer's disease, Lewy body diseases and Guam parkinsonism-dementia complex. We therefore aimed to determine whether there is TDP-43 pathology in human prion diseases, which are characterised by variable deposition of prion protein (PrP) aggregates in the brain as amyloid plaques or more diffuse deposits.
###end p 3
###begin title 4
Material and methods
###end title 4
###begin p 5
###xml 150 155 <span type="species:ncbi:9606">human</span>
TDP-43, ubiquitin and PrP were analysed by immunohistochemistry and double-labelling immunofluorescence, in sporadic, acquired and inherited forms of human prion disease.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
Most PrP plaques contained ubiquitin, while synaptic PrP deposits were not associated with ubiquitin. No abnormal TDP-43 inclusions were identified in any type of prion disease case, and TDP-43 did not co-localize with ubiquitin-positive PrP plaques or with diffuse PrP aggregates.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
These data do not support a role for TDP-43 in prion disease pathogenesis and argue that TDP-43 inclusions define a distinct group of neurodegenerative disorders.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 364 365 364 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 456 457 456 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 458 459 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 537 538 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 539 540 539 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 578 579 578 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 608 609 608 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
TAR-DNA binding protein-43 (TDP-43) has recently been identified as the major protein in the ubiquitinated inclusions that characterize frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions (FTLD-U) and motor neurone disease (MND) [1]. TDP-43 pathology has since been reported in ubiquitinated inclusions in Alzheimer's disease cases [2,3], in Guam parkinsonism-dementia complex brains [4,5] and in Lewy body-related diseases [3,6]. Occasional TDP-43 staining has also been noted in neurofibrillary tangles [2,3,7] and in corticobasal degeneration [7] and Pick's disease brains [7,8]. These findings show that a number of neurodegenerative diseases characterized by protein aggregation have pathological TDP-43 immunoreactivity, prompting us to look in prion disease brains, which also contain protein aggregates.
###end p 11
###begin p 12
###xml 168 169 168 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 226 228 226 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human prion diseases are a clinically and neuropathologically diverse group of neurodegenerative disorders in which conversion of host-encoded prion protein, termed PrPC, to an abnormally folded and aggregated form, termed PrPSc, is a central feature [9,10].
###end p 12
###begin p 13
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 206 210 206 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 213 214 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 360 364 360 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 598 602 598 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 664 668 664 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
Approximately 85% of human prion diseases occur as sporadic Creutzfeldt-Jakob disease (CJD) [11], and approximately 15% of human prion diseases are inherited, caused by mutations in the prion protein gene (PRNP) [9]. Susceptibility to sporadic prion diseases, as well as the acquired prion diseases described below, is affected by the genotype at codon 129 of PRNP [12-17]. Traditionally, the inherited cases have been classified as Gerstmann-Straussler-Scheinker disease (GSS), fatal familial insomnia (FFI) or CJD; however, the range of clinical presentations, even within families with the same PRNP mutation [18-22], has led to sub-classification based on the PRNP mutation and the genotype at codon 129 [20,23].
###end p 13
###begin p 14
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 773 775 773 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 863 865 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">32</xref>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 336 341 <span type="species:ncbi:9606">human</span>
###xml 630 636 <span type="species:ncbi:9913">bovine</span>
###xml 726 732 <span type="species:ncbi:9913">cattle</span>
Acquired prion diseases are a rare cause of prion disease in most populations, but can have a high frequency in certain populations. Acquired prion diseases can be classified as kuru, iatrogenic CJD or variant CJD (vCJD). Iatrogenic CJD has been caused by prion exposure from medical and surgical procedures, such as dura mater grafts, human growth hormone treatment and contamination of surgical equipment [24,25]. vCJD was first identified in the UK in 1995 as a novel variant of CJD [26], and generally has a much earlier age of onset than sporadic CJD [27]. The prion strain identified in vCJD has the same characteristics as bovine spongiform encephalopathy (BSE) prions, suggesting that dietary exposure to BSE-infected cattle was the cause for the vCJD outbreak [28-31]. There is now strong evidence that vCJD can also be transmitted by blood transfusion [32-34].
###end p 14
###begin p 15
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 746 748 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
There are several characteristic neuropathological changes in the prion diseases described above: neuronal loss, astrocytic gliosis and spongiform vacuolation [35]. The latter can be absent in FFI [36] and can also be absent in severely 'burnt-out' areas, in which few neurons remain. Abnormal accumulation of PrP is generally observed, but the extent and form are variable [35] and, like spongiosis, is occasionally not observed in FFI [35,36]. GSS and kuru are characterized by PrP-positive amyloid plaques [35,37], while in sporadic CJD diffuse synaptic accumulation of PrP, which can also be seen in GSS, is more common [35,37]. vCJD is characterized by abundant florid amyloid plaques, in which the surrounding tissue is microvacuolated [26,38], but diffuse deposits can be seen as well.
###end p 15
###begin p 16
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
Ubiquitin immunohistochemistry (IHC) in sporadic CJD and GSS has previously revealed staining at the periphery of amyloid plaques and around areas of spongiform change [39]. Because TDP-43 pathology can be associated with ubiquitinated deposits, and has now been observed in a number of neurodegenerative diseases, we analysed ubiquitin, PrP and TDP-43 immunoreactivity in different forms of prion diseases, including sporadic, inherited and acquired cases. PrP plaques were often accompanied by punctate ubiquitin deposits, but both PrP and ubiquitin staining were not associated with any TDP-43 cytoplasmic accumulation, suggesting that TDP-43 is probably not involved in prion disease pathogenesis.
###end p 16
###begin title 17
Materials and methods
###end title 17
###begin title 18
###xml 7 12 <span type="species:ncbi:9606">human</span>
Use of human tissues
###end title 18
###begin p 19
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human tissues were obtained at autopsy with consent for use in research. This study was approved by the UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery Local Research Ethics Committee.
###end p 19
###begin title 20
Antibodies
###end title 20
###begin p 21
###xml 257 261 257 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Prnp</italic>
###xml 261 264 261 264 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o/o</sup>
###xml 324 326 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">40</xref>
###xml 265 269 <span type="species:ncbi:10090">mice</span>
Anti-TDP-43 (ProteinTech Group, Chicago, IL, USA), 1:10 000 for IHC, 1:150 for immunofluorescence (IF). Anti-ubiquitin (SC-8017, Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:5000 for IHC, 1:2500 for IF. Anti-PrP ICSM35 (D-Gen, London, UK) was raised in Prnpo/o mice against recombinant beta-PrP as previously described [40] and was used at 1:1000 for IHC and 1:500 for IF.
###end p 21
###begin title 22
Immunohistochemistry
###end title 22
###begin p 23
###xml 576 577 566 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
Formalin-fixed brain samples were immersed in 98% formic acid for 1 h to denature infectious prions. Brain samples were then processed and 10-microm paraffin sections were cut and allowed to dry overnight at room temperature, then baked for 2 h at 60degreesC. Sections were pre-treated by boiling in 1 M citrate buffer pH 6.0 (TDP-43 and ubiquitin antibodies) and tris-EDTA-citrate buffer pH 7.8 (ICSM35). For specific detection of aggregated disease-associated PrP with ICSM35, sections were immersed in 98% formic acid for 5 min and treated with proteases to abolish the PrPC signal. IHC was carried out on an automated immunostaining machine (Benchmark, Ventana Medical Systems Inc., Tucson, AZ, USA) using proprietary protease and secondary detection reagents and developed with 3'3 diaminobenzedine tetrachloride as the chromogen. Sections were counterstained with haematoxylin. Bright field photographs were taken on an ImageView II 3.5 Mpix digital camera (Soft Imaging Solutions GmbH, Munster, Germany, ) mounted on a ZEISS Axioplan microscope (Carl Zeiss Jena GmbH, Jena, Germany) and composed with Adobe Photoshop (Adobe Systems Incorporated, San Jose, CA, USA).
###end p 23
###begin title 24
Double-labelling IF
###end title 24
###begin p 25
###xml 565 571 <span type="species:ncbi:9986">rabbit</span>
###xml 594 599 <span type="species:ncbi:10090">mouse</span>
Sections were pre-treated by pressure cooking for 20 min in 1 M citrate buffer pH 6.0 (ubiquitin and TDP-43 double labelling); 20-min pressure cooking in 1 M citrate buffer pH 6.0 followed by protease treatment (ubiquitin and ICSM35 double labelling); or pressure cooking for 20 min in 1 M citrate buffer pH 6.0 followed by 98% formic acid for 5 min and then protease treatment (TDP-43 and ICSM35 double labelling). Sections were manually stained sequentially for each primary antibody followed by detection with the relevant secondary antibodies; Alexa Fluor anti-rabbit 488; Alexa Fluor anti-mouse 546, Alexa Fluor anti-IgG1 488; Alexa Fluor anti-IgG2b 546 (all from Invitrogen, Carlsbad, CA, USA and used at 1:400). Laser scanning confocal microscopy was performed with a Zeiss LSM510 META, mounted on Zeiss Axiovert 200 M. All images were recorded using a ZEISS Plan-Apochromat 20x/0.75 objective. Image analysis was performed using Zeiss LSM software.
###end p 25
###begin title 26
Results
###end title 26
###begin title 27
PrP plaques but not diffuse PrP aggregates contain ubiquitin deposits
###end title 27
###begin p 28
###xml 326 333 326 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
We initially examined PrP and ubiquitin immunoreactivity in the frontal cortex of a variety of inherited prion disease cases as well as sporadic, iatrogenic and variant CJD samples. In addition, we also analysed the cerebellum of a case with diagnosed GSS carrying a P102L mutation. Details of the cases examined are given in Table 1.
###end p 28
###begin p 29
Clinical and genetic data, and PrP and ubiquitin staining in the prion disease cases
###end p 29
###begin p 30
Localized to deep cortical layers only.
###end p 30
###begin p 31
Axonal and dendritic PrP only.
###end p 31
###begin p 32
Diffuse PrP plaques.
###end p 32
###begin p 33
Scoring for abnormal PrP immunoreactivity was as follows: 0, no staining; +, mild pathology; ++, moderate pathology, +++, severe pathology. Frontal cortex and hippocampus were analysed for all cases. Cerebellum was additionally examined in the P102L (GSS) case. All figures show frontal cortex staining except for the P102L (GSS) case for which cerebellum is shown. Column 1 indicates case number which is also shown in the figures and column 2 indicates the figures in which images of each case are shown.
###end p 33
###begin p 34
###xml 233 234 233 234 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</underline>
###xml 237 238 237 238 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</underline>
###xml 245 246 245 246 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</underline>
###xml 252 253 252 253 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</underline>
###xml 294 298 294 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">41</xref>
FFI, fatal familial insomnia; FTLD, frontotemporal lobar degeneration; GSS, Gerstmann-Straussler-Scheinker disease; iCJD, iatrogenic CJD from exposure to contaminated growth hormone; vCJD, variant CJD; sCJD, sporadic CJD; 6OPRI, six-octapeptide-repeat insertion - an insertion of 144 bp in the PRNP gene, coding for six repeats of an octapeptide motif [41]; UA, unavailable; ND, not determined.
###end p 34
###begin p 35
###xml 346 347 346 347 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 348 349 348 349 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 338 349 338 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1<bold>A</bold>,<bold>D</bold></xref>
###xml 443 447 443 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 457 458 457 458 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">J</bold>
###xml 449 458 449 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2<bold>J</bold></xref>
###xml 786 787 786 787 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 778 787 778 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2<bold>G</bold></xref>
###xml 886 887 886 887 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</bold>
###xml 878 887 878 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2<bold>M</bold></xref>
###xml 1093 1094 1093 1094 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</bold>
###xml 1085 1094 1085 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Figure 2<bold>N</bold></xref>
###xml 1199 1207 1199 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Figure 3</xref>
###xml 1298 1306 1298 1306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Figure 3</xref>
###xml 1393 1394 1393 1394 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1385 1394 1385 1394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Figure 3<bold>F</bold></xref>
Disease-associated PrP was detected with the monoclonal antibody ICSM35 as described in the methods. We scored the abundance of PrP plaques and diffuse PrP aggregates for each case in a semi-quantitative assessment, and analysed ubiquitin pathology in these scored cases. As expected, vCJD brains contained abundant PrP-positive plaques (Figure 1A,D), as did one inherited prion disease case with a six-octapeptide-repeat insertion (6OPRI) in PRNP (Figure 2J). Interestingly, another case with the same 6OPRI insertion mutation had no PrP plaques, but rather fine axonal and dendritic PrP staining in grey and white matter, confirming the neuropathological heterogeneity even of cases with the same mutation (data not shown). The P102L (GSS) brain contained mature PrP plaques (Figure 2G), while the D178N (FFI) case had more diffuse or primitive plaques (but no core plaques) (Figure 2M). PrP plaques were consistently dotted with small ubiquitin aggregates, except in the D178N (FFI) case in which the correlation between the diffuse plaques and ubiquitin deposits was less obvious (Figure 2N). The plaques could be clearly identified by ubiquitin immunoreactivity using both standard IHC and IF (Figure 3). Double labelling confirmed the presence of small ubiquitin deposits within PrP plaques (Figure 3), and also showed that some D178N (FFI) plaques contained ubiquitin deposits (Figure 3F).
###end p 35
###begin p 36
###xml 226 227 226 227 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 228 229 228 229 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 450 451 450 451 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 452 453 452 453 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 549 550 549 550 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 551 552 551 552 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</bold>
###xml 803 804 803 804 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">J</bold>
###xml 820 821 820 821 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</bold>
###xml 962 969 962 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 1004 1005 1000 1001 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1006 1007 1002 1003 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1031 1032 1023 1024 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 1037 1038 1029 1030 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</bold>
###xml 1057 1058 1045 1046 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">J</bold>
###xml 1063 1064 1051 1052 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</bold>
Prion protein (PrP), ubiquitin and TAR-DNA binding protein-43 (TDP-43) staining in acquired prion diseases: In all cases, prion protein plaques co-localize with ubiquitin aggregates, but no TDP-43 abnormalities are observed. (A-C) Variant Creutzfeldt-Jakob disease (vCJD) with characteristic dense PrP deposits surrounded by vacuolations ('florid plaques'). Even in close proximity to the plaques, there is no abnormal nuclear deposition of TDP-43. (D-F) Abundant plaques in another vCJD case, again co-localizing with ubiquitin granular deposits. (G-I) Synaptic and plaque deposits in iatrogenic CJD, which contain ubiquitin but not TDP-43. Progranulin-positive frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions (FTLD-U) case showing neuritic pathology in the absence (J), or presence (K) of formic acid treatment. An intranuclear inclusion is also apparent in the formic acid-treated sample. Numbers indicate case numbers (see Table 1). Scale bar: 50 microm for images A-F, 100 microm for images G and H and 36 microm for J and K.
###end p 36
###begin p 37
###xml 123 124 123 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 125 126 125 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 233 234 233 234 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 235 236 235 236 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 237 238 237 238 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">J</bold>
###xml 239 240 239 240 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</bold>
###xml 314 315 314 315 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 316 317 316 317 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 439 440 439 440 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 441 443 441 443 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I)</bold>
###xml 526 527 526 527 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">J</bold>
###xml 528 529 528 529 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</bold>
###xml 677 678 677 678 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">J</bold>
###xml 728 729 728 729 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</bold>
###xml 759 760 759 760 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</bold>
###xml 761 762 761 762 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</bold>
###xml 794 795 794 795 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</bold>
###xml 898 905 898 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 951 952 947 948 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 954 955 950 951 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</bold>
###xml 957 958 953 954 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 960 961 956 957 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</bold>
###xml 966 967 962 963 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</bold>
Prion protein (PrP), ubiquitin and TAR-DNA binding protein-43 (TDP-43) staining in sporadic and inherited prion diseases. (A-C) sCJD with synaptic PrP deposition, very little punctate ubiquitin deposits and normal TDP-43 labelling. (D,G,J,M) Inherited prion diseases with various types of prion protein deposits. (D-F) A117V mutation with diffuse, synaptic deposits, again with no marked ubiquitin deposition and no TDP-43 abnormalities. (G-I) GSS with P102L mutation shows marked ubiquitin aggregates in and around plaques. (J-L) Case of six-octapeptide-repeat insertion (144-bp insert) with abundant, dense prion protein deposits, mainly presenting with 'primitive' plaques (J), which are accompanied by ubiquitin aggregates (K), but no changes in TDP-43. (M-O) FFI with diffuse PrP plaques (M), no ubiquitin and no TDP-43 abnormalities. Numbers below the disease type indicate case numbers (see Table 1). Scale bar 100 microm for all images except C, I, F, L and O for which the scale bar is 50 microm.
###end p 37
###begin p 38
###xml 276 277 276 277 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 278 279 278 279 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 362 365 362 365 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D&#8211;F</bold>
###xml 354 365 354 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1<bold>D&#8211;F</bold></xref>
###xml 457 458 457 458 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 513 514 513 514 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 518 519 518 519 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 621 623 621 623 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A)</bold>
###xml 761 762 761 762 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 763 764 763 764 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 799 802 799 802 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A&#8211;C</bold>
###xml 940 941 940 941 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 946 947 946 947 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 954 955 954 955 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 960 961 960 961 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 963 964 963 964 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 965 966 965 966 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</bold>
###xml 1206 1209 1206 1209 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M,P</bold>
###xml 1222 1223 1222 1223 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</bold>
###xml 1279 1280 1279 1280 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q</bold>
###xml 1396 1397 1396 1397 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</bold>
###xml 1398 1399 1398 1399 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</bold>
###xml 1506 1507 1502 1503 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</bold>
Double-labelling immunofluorescence for prion protein (PrP), ubiquitin and TAR-DNA binding protein-43 (TDP-43). Demonstration of close association of PrP and ubiquitin in plaques, but not in synaptic deposits. No TDP-43 abnormalities in cases of synaptic or plaque deposits. (A-C) Variant Creutzfeldt-Jakob disease with abundant florid plaques (see also Figure 1D-F) shows numerous granular ubiquitin deposits with no impact on nuclear labelling of TDP-43 (A), likewise no TDP-43 abnormality around PrP deposits (B). (C) Close association of ubiquitin with PrP labelling. The slightly weaker ubiquitin labelling than in (A) is a result of the different pre-treatment of the sections to visualize PrP, resulting in some quenching of ubiquitin immunoreactivity. (D-F) FFI with similar findings as in (A-C). The area void of TDP-43 labelling in the centre of the plaque is due to the loss or displacement of neurons in the area of the plaque. E and F as in B and C. G-L show little ubiquitin staining due to the absence of PrP plaques. In contrast, prion diseases with abundant plaques show more abundant ubiquitin in plaques, and a reduction of TDP-43 in the very centre of the plaque, due to neuronal loss (M,P). Arrows in P indicate punctate ubiquitin staining around a plaque. (Q) Gerstmann-Straussler-Scheinker disease plaques in the cerebellar molecular layer (the granular layer is on top). (O,R) Close association of ubiquitin deposits with plaque protein. Scale bar, 100 microm for all images except I (200 microm).
###end p 38
###begin p 39
###xml 161 168 161 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 170 179 170 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figures 1</xref>
###xml 184 185 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">2</xref>
###xml 299 307 299 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Figure 3</xref>
Diffuse synaptic PrP aggregates were observed in the sporadic CJD cases as well as in other cases, but did not show any apparent co-localization with ubiquitin (Table 1, Figures 1 and 2). The lack of co-localization between diffuse PrP aggregates and ubiquitin was confirmed by double-labelling IF (Figure 3). These data suggest that PrP plaques, but not diffuse PrP pathology, contain ubiquitin deposits.
###end p 39
###begin title 40
###xml 32 37 <span type="species:ncbi:9606">human</span>
PrP and ubiquitin aggregates in human prion diseases are TDP-43-negative
###end title 40
###begin p 41
###xml 276 285 276 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figures 1</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">2</xref>
###xml 405 413 405 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Figure 3</xref>
The TDP-43 immunoreactivity was initially analysed in the frontal cortex of all of the prion disease cases described. TDP-43 was nuclear in all cases, and did not appear to co-localize with diffuse PrP, PrP plaques or plaque-associated ubiquitin deposits in any of the cases (Figures 1 and 2). No co-localization of TDP-43 with ubiquitin, or TDP-43 with PrP aggregates was seen using double-labelling IF (Figure 3).
###end p 41
###begin p 42
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
###xml 936 938 936 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">43</xref>
###xml 939 941 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
Abnormal TDP-43 accumulation has also been reported in the hippocampus in Alzheimer's disease and dementia with Lewy bodies [3]. Therefore, we also analysed TDP-43 immunoreactivity in the hippocampus in all cases, and similarly to frontal cortex found no abnormalities (data not shown). TDP-43 pathology has been reported in the absence of ubiquitin immunoreactivity in both white and grey matter of FTLD-U cases [42-44] and Guam parkinsonism-dementia complex cases [5]. We examined TDP-43 in the white matter and in grey matter areas not associated with PrP pathology in both hippocampus and frontal cortex, but did not observe any abnormal TDP-43 staining. Re-localization of TDP-43 from the nucleus to cytoplasmic aggregates appears to be a characteristic finding in TDP-43 proteinopathies, but reduced nuclear staining due to granular cytoplasmic TDP-43 immunoreactivity, rather than distinct inclusions, has also been reported [42,43,45]. We therefore also examined the frontal cortex and hippocampus of prion disease cases for instances of cytoplasmic rather than nuclear TDP-43 localization, but did not observe any such staining.
###end p 42
###begin p 43
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">46</xref>
###xml 635 636 635 636 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">J</bold>
###xml 637 638 637 638 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</bold>
###xml 627 638 627 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Figure 1<bold>J</bold>,<bold>K</bold></xref>
One possible confounding factor is that all formalin-fixed prion disease brains were immersed in formic acid prior to processing to abolish prion infectivity. To exclude the possibility that formic acid treatment alters pathological TDP-43 immunoreactivity (normal nuclear staining of TDP-43 was very strong in formic acid-treated brains), we analysed two progranulin-positive FTLD-U cases [46]. For each FTLD-U case, two samples of frontal cortex were processed separately, either with or without formic acid treatment. Immunostaining revealed extensive TDP-43 pathology in both the formic acid-treated and untreated samples (Figure 1J,K), confirming that the lack of TDP-43 pathology in our prion disease brains was not due to formic acid treatment. These data therefore show that TDP-43 pathology is not observed in a wide range of prion brains with differing PrP pathology.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 237 238 237 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
TDP-43 was initially shown to be the major ubiquitinated protein in the inclusions in FTLD-U and MND [1]. Subsequently, TDP-43 pathology was identified in Alzheimer's disease, Guam parkinsonism-dementia complex and Lewy body diseases [2-6]. It is therefore important to define the range of neurodegenerative diseases with protein aggregates that harbour TDP-43 pathology.
###end p 45
###begin p 46
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 333 338 <span type="species:ncbi:9606">human</span>
Prion disease brains usually contain PrP aggregates, and a previous study showed ubiquitin staining in the periphery of plaques in GSS and sporadic cases, as well as ubiquitin immunoreactivity around areas of spongiform change [39]. We have now extended the analysis of ubiquitin in prion disease brains by examining a wide range of human prion disease cases including variant CJD and a variety of inherited cases with distinct pathological features. We did not observe ubiquitin in areas of spongiform change, as was previously described, which may be due to differences in antibody specificity or sensitivity, or the particular staining and pre-treatment protocols used. We show here that PrP plaques, but not diffuse (synaptic) PrP aggregates, contain ubiquitin deposits. Interestingly, the more diffuse PrP plaques in FFI stained less often for ubiquitin than more compact PrP plaques, possibly indicating that compaction of plaques facilitates their ubiquitination or that ubiquitin is sequestered into compact plaques.
###end p 46
###begin p 47
###xml 990 994 990 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 1035 1037 1035 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">47</xref>
###xml 1038 1040 1038 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">49</xref>
###xml 1085 1089 1085 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 1127 1129 1127 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">50</xref>
###xml 1130 1132 1130 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">52</xref>
###xml 1493 1495 1493 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53">53</xref>
###xml 1496 1498 1496 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54">54</xref>
###xml 1526 1528 1526 1528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
###xml 1529 1531 1529 1531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55">55</xref>
We examined a number of different cases of prion disease with ubiquitin-positive PrP plaques. Ubiquitin deposits were always negative for TDP-43, and TDP-43 did not show abnormal cytoplasmic aggregation nearby or distant from plaques. TDP-43 was also normal in areas with diffuse PrP aggregates and in areas without any abnormal PrP immunoreactivity, including the white matter. These data suggest that TDP-43 is probably not involved in the pathogenesis or progression of prion diseases. TDP-43 pathology, therefore, appears to be specific to a subset of neurodegenerative diseases, which may share some aetiological features. Understanding the role and significance of TDP-43 in these cases is now a fundamental question in the field, and helping to define the clinical spectrum of TDP-43 proteinopathies, as we have done here, is an important first step in this process. Prion diseases and TDP-43 proteinopathies share the feature of protein aggregation, and there is some evidence that PRNP may have a role in Alzheimer's disease [47-49]. There is also conflicting data on whether PRNP genotype can affect the risk of FTD [50-52]. However, the lack of TDP-43 pathology in prion diseases suggests that if there is a common pathogenic pathway with TDP-43 proteinopathies, it is downstream of TDP-43. This could also be the case with certain disorders that are in the clinical and neuropathological spectrum of TDP-43 proteinopathies but which are TDP-43-negative, such as SOD1-positive MND [53,54] and certain FTLD-U cases [42,55].
###end p 47
###begin p 48
###xml 15 20 <span type="species:ncbi:9606">human</span>
In conclusion, human prion diseases do not have detectable TDP-43 pathology, further defining the spectrum of TDP-43 proteinopathies.
###end p 48
###begin p 49
###xml 81 89 <span type="species:ncbi:9606">patients</span>
This work was funded by the UK Medical Research Council. We gratefully thank all patients and families involved for consent to use of tissues in this research and colleagues in neurology and neuropathology throughout the UK for case referral to the National Prion Clinic. We thank Prof. Tamas Revesz and Mrs Linda Parsons (Queen Square Brain Bank) for provision of FTLD-U brain tissue.
###end p 49
###begin title 50
Disclosure
###end title 50
###begin p 51
JC is a director and shareholder of D-Gen Ltd, an academic spin-out company which markets anti-PrP monoclonal antibody ICSM35.
###end p 51
###begin title 52
References
###end title 52
###begin article-title 53
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
###end article-title 53
###begin article-title 54
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
###end article-title 54
###begin article-title 55
Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies
###end article-title 55
###begin article-title 56
Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam
###end article-title 56
###begin article-title 57
TDP-43 is deposited in the Guam parkinsonism-dementia complex brains
###end article-title 57
###begin article-title 58
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases
###end article-title 58
###begin article-title 59
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
###end article-title 59
###begin article-title 60
TAR-DNA binding protein 43 in Pick disease
###end article-title 60
###begin article-title 61
###xml 18 24 <span type="species:ncbi:9606">humans</span>
Prion diseases of humans and animals: their causes and molecular basis
###end article-title 61
###begin article-title 62
Prions
###end article-title 62
###begin article-title 63
The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-year investigation in France and review of the world literature
###end article-title 63
###begin article-title 64
Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease
###end article-title 64
###begin article-title 65
Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease
###end article-title 65
###begin article-title 66
Increased susceptibility to Kuru of carriers of the PRNP 129 methionine/methionine genotype
###end article-title 66
###begin article-title 67
Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease
###end article-title 67
###begin article-title 68
Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene
###end article-title 68
###begin article-title 69
Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics
###end article-title 69
###begin article-title 70
Prion dementia without characteristic pathology
###end article-title 70
###begin article-title 71
Diagnosis of Gerstmann-Straussler syndrome in familial dementia with prion protein gene analysis
###end article-title 71
###begin article-title 72
Inherited prion disease with 144 base pair gene insertion. 2. Clinical and pathological features
###end article-title 72
###begin article-title 73
Mutations of the prion protein gene phenotypic spectrum
###end article-title 73
###begin article-title 74
Inherited prion disease with an alanine to valine mutation at codon 117 in the prion protein gene
###end article-title 74
###begin article-title 75
Terminology of prion disease
###end article-title 75
###begin article-title 76
Iatrogenic Creutzfeldt-Jakob disease at the millennium
###end article-title 76
###begin article-title 77
Friendly fire' in medicine: hormones, homografts, and Creutzfeldt-Jakob disease
###end article-title 77
###begin article-title 78
A new variant of Creutzfeldt-Jakob disease in the UK
###end article-title 78
###begin article-title 79
First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features
###end article-title 79
###begin article-title 80
###xml 86 101 <span type="species:ncbi:10090">transgenic mice</span>
###xml 113 118 <span type="species:ncbi:9606">human</span>
BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein
###end article-title 80
###begin article-title 81
###xml 17 21 <span type="species:ncbi:10090">mice</span>
Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent
###end article-title 81
###begin article-title 82
The same prion strain causes vCJD and BSE
###end article-title 82
###begin article-title 83
Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD
###end article-title 83
###begin article-title 84
Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion
###end article-title 84
###begin article-title 85
###xml 74 81 <span type="species:ncbi:9606">patient</span>
Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient
###end article-title 85
###begin article-title 86
Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report
###end article-title 86
###begin article-title 87
Neuropathology of prion diseases
###end article-title 87
###begin article-title 88
Fatal familial insomnia: a new Austrian family
###end article-title 88
###begin article-title 89
###xml 84 89 <span type="species:ncbi:9606">human</span>
Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases)
###end article-title 89
###begin article-title 90
Neuropathology and molecular biology of variant Creutzfeldt-Jakob disease
###end article-title 90
###begin article-title 91
###xml 33 38 <span type="species:ncbi:9606">human</span>
Ubiquitin immunocytochemistry in human spongiform encephalopathies
###end article-title 91
###begin article-title 92
PrP glycoforms are associated in a strain-specific ratio in native PrPSc
###end article-title 92
###begin article-title 93
Inherited prion disease with six octapeptide repeat insertional mutation-molecular analysis of phenotypic heterogeneity
###end article-title 93
###begin article-title 94
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions
###end article-title 94
###begin article-title 95
Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein TDP-43
###end article-title 95
###begin article-title 96
TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions
###end article-title 96
###begin article-title 97
Anterior horn cells with abnormal TDP-43 immunoreactivities show fragmentation of the Golgi apparatus in ALS
###end article-title 97
###begin article-title 98
A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series
###end article-title 98
###begin article-title 99
PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease
###end article-title 99
###begin article-title 100
Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein
###end article-title 100
###begin article-title 101
Prion protein codon 129 polymorphism and risk of Alzheimer disease
###end article-title 101
###begin article-title 102
Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia
###end article-title 102
###begin article-title 103
Prion protein (PRNP) genotypes in frontotemporal lobar degeneration syndromes
###end article-title 103
###begin article-title 104
Frontal lobe or 'nonspecific' dementias are genetically heterogeneous
###end article-title 104
###begin article-title 105
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations
###end article-title 105
###begin article-title 106
TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation
###end article-title 106
###begin article-title 107
A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3
###end article-title 107

